Concepts (80)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pacemaker, Artificial | 4 | 2024 | 49 | 3.100 |
Why?
|
| Catheter Ablation | 5 | 2025 | 155 | 1.650 |
Why?
|
| Thromboembolism | 3 | 2024 | 73 | 0.980 |
Why?
|
| Tachycardia, Atrioventricular Nodal Reentry | 1 | 2025 | 6 | 0.950 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2025 | 10 | 0.950 |
Why?
|
| Ablation Techniques | 1 | 2025 | 24 | 0.930 |
Why?
|
| Anticoagulants | 4 | 2024 | 496 | 0.900 |
Why?
|
| Perioperative Care | 2 | 2024 | 85 | 0.870 |
Why?
|
| Syncope, Vasovagal | 1 | 2023 | 8 | 0.820 |
Why?
|
| High-Frequency Jet Ventilation | 1 | 2022 | 2 | 0.750 |
Why?
|
| Atrial Fibrillation | 6 | 2024 | 835 | 0.750 |
Why?
|
| High-Frequency Ventilation | 1 | 2022 | 5 | 0.740 |
Why?
|
| Defibrillators, Implantable | 1 | 2024 | 267 | 0.710 |
Why?
|
| Patient Discharge | 1 | 2022 | 512 | 0.600 |
Why?
|
| Cardiac Pacing, Artificial | 3 | 2023 | 36 | 0.590 |
Why?
|
| Treatment Outcome | 6 | 2025 | 5699 | 0.330 |
Why?
|
| Administration, Oral | 2 | 2024 | 369 | 0.230 |
Why?
|
| Action Potentials | 1 | 2025 | 105 | 0.230 |
Why?
|
| Hematoma | 1 | 2024 | 81 | 0.220 |
Why?
|
| Humans | 11 | 2025 | 63511 | 0.210 |
Why?
|
| Heart Rate | 1 | 2025 | 322 | 0.210 |
Why?
|
| Hypotension | 1 | 2024 | 50 | 0.210 |
Why?
|
| Recurrence | 1 | 2025 | 644 | 0.210 |
Why?
|
| Body Surface Potential Mapping | 2 | 2013 | 4 | 0.200 |
Why?
|
| Equipment Design | 2 | 2022 | 358 | 0.200 |
Why?
|
| Heart Conduction System | 2 | 2013 | 53 | 0.190 |
Why?
|
| Equipment Failure | 1 | 2022 | 68 | 0.190 |
Why?
|
| Tidal Volume | 1 | 2022 | 41 | 0.180 |
Why?
|
| Middle Aged | 7 | 2025 | 17644 | 0.180 |
Why?
|
| Aged | 5 | 2025 | 14472 | 0.160 |
Why?
|
| Hypertension | 2 | 2024 | 587 | 0.160 |
Why?
|
| Prospective Studies | 3 | 2022 | 3301 | 0.150 |
Why?
|
| Risk Assessment | 1 | 2025 | 2082 | 0.140 |
Why?
|
| Time Factors | 1 | 2025 | 3770 | 0.140 |
Why?
|
| Pandemics | 1 | 2022 | 673 | 0.140 |
Why?
|
| Risk Factors | 1 | 2025 | 5359 | 0.110 |
Why?
|
| Thiophenes | 1 | 2014 | 29 | 0.110 |
Why?
|
| Morpholines | 1 | 2014 | 89 | 0.100 |
Why?
|
| Cardiac Catheters | 1 | 2012 | 12 | 0.100 |
Why?
|
| Electrodes, Implanted | 1 | 2012 | 38 | 0.100 |
Why?
|
| Heart Atria | 1 | 2013 | 137 | 0.090 |
Why?
|
| beta-Alanine | 1 | 2012 | 8 | 0.090 |
Why?
|
| Male | 6 | 2025 | 29927 | 0.090 |
Why?
|
| Benzimidazoles | 1 | 2012 | 54 | 0.090 |
Why?
|
| Registries | 2 | 2014 | 893 | 0.090 |
Why?
|
| Image Enhancement | 1 | 2012 | 192 | 0.090 |
Why?
|
| Adult | 2 | 2025 | 16837 | 0.090 |
Why?
|
| Warfarin | 1 | 2012 | 111 | 0.090 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2013 | 284 | 0.090 |
Why?
|
| Female | 6 | 2025 | 32912 | 0.090 |
Why?
|
| Software | 1 | 2013 | 390 | 0.080 |
Why?
|
| Algorithms | 1 | 2013 | 1003 | 0.070 |
Why?
|
| Feasibility Studies | 3 | 2014 | 572 | 0.060 |
Why?
|
| Angiotensinogen | 1 | 2024 | 3 | 0.050 |
Why?
|
| Antihypertensive Agents | 1 | 2024 | 169 | 0.050 |
Why?
|
| Double-Blind Method | 1 | 2024 | 741 | 0.050 |
Why?
|
| Blood Pressure | 1 | 2024 | 512 | 0.040 |
Why?
|
| RNA Interference | 1 | 2024 | 618 | 0.040 |
Why?
|
| RNA | 1 | 2024 | 423 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2013 | 1147 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2013 | 1655 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2014 | 2462 | 0.030 |
Why?
|
| Postoperative Complications | 2 | 2014 | 1311 | 0.030 |
Why?
|
| Perioperative Period | 1 | 2014 | 21 | 0.030 |
Why?
|
| Rivaroxaban | 1 | 2014 | 19 | 0.030 |
Why?
|
| Factor Xa Inhibitors | 1 | 2014 | 35 | 0.030 |
Why?
|
| Equipment Failure Analysis | 1 | 2012 | 75 | 0.020 |
Why?
|
| Dabigatran | 1 | 2012 | 20 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 864 | 0.020 |
Why?
|
| Swine | 1 | 2012 | 380 | 0.020 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2012 | 101 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2012 | 164 | 0.020 |
Why?
|
| Hemorrhage | 1 | 2012 | 268 | 0.020 |
Why?
|
| Sex Factors | 1 | 2012 | 978 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2012 | 554 | 0.020 |
Why?
|
| Echocardiography | 1 | 2012 | 502 | 0.020 |
Why?
|
| Incidence | 1 | 2012 | 1380 | 0.020 |
Why?
|
| Age Factors | 1 | 2012 | 1561 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2012 | 6673 | 0.010 |
Why?
|
| Animals | 1 | 2012 | 20666 | 0.010 |
Why?
|